emricasan   Click here for help

GtoPdb Ligand ID: 6508

Synonyms: IDN-6556 | PF-03491390
Compound class: Synthetic organic
Comment: Emricasan is a pan caspase inhibitor. Its development as a treatment for nonalcoholic steatohepatitis (NASH) was unsuccessful.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 4
Rotatable bonds 15
Topological polar surface area 150.9
Molecular weight 569.18
XLogP 3.1
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(=O)CC(C(=O)COc1c(F)c(F)cc(c1F)F)NC(=O)C(NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C
Isomeric SMILES OC(=O)C[C@@H](C(=O)COc1c(F)c(F)cc(c1F)F)NC(=O)[C@@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C
InChI InChI=1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1
InChI Key SCVHJVCATBPIHN-SJCJKPOMSA-N
No information available.
Summary of Clinical Use Click here for help
Clinical candidate being investigated as a treatment for liver failure, including that ensuing from hepatitis C infection and nonalcoholic steatohepatitis. Click here to view emricasan related clinical trials registered with ClinicalTrials.gov. This drug candidate has been granted orphan designation by the US FDA, for the treatment of liver transplant patients with reestablished fibrosis. Drug treatment is intended to delay the progression to cirrhosis and end-stage liver disease in these patients.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Emricasan irreversibly inhibits caspase proteases and is designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. It is postulated that this action has the potential to interrupt the progression of liver disease [1].